Summary
0J8Z Chart
Should You Add Illumina Stock to Your Portfolio Now?
ILMN's sequencing growth, oncology momentum and multiomics expansion support its outlook, though cost volatility may pressure margins.
Illumina, Inc. Post Earnings: Buy On A Pullback
Illumina delivered strong Q2 2026 results, beating on EPS and revenue, and raised full-year guidance for both metrics. ILMN's profitability and momentum are robust, with management emphasizing margin expansion, ongoing share buybacks, and significant cash flow. Despite a D- valuation and stagnant historical revenue, Wall Street analysts are revising growth estimates upward, anticipating a revenue breakout by 2027.
Illumina (ILMN) is a Top-Ranked Growth Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Illumina, Inc. (0J8Z) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Illumina, Inc. ever had a stock split?
Illumina, Inc. Profile
| Professional Services Industry | Industrials Sector | Jacob Thaysen CEO | LSE Exchange | 452327109 CUSIP |
| US Country | 8,600 Employees | - Last Dividend | 25 Jun 2024 Last Split | 28 Jul 2000 IPO Date |
Overview
Illumina, Inc. is a leader in the development and manufacturing of sequencing- and array-based solutions designed for genetic and genomic analysis. With operations spanning the United States, Singapore, the United Kingdom, and other international markets, Illumina serves a diverse set of customers, including genomic research centers, academic institutions, government laboratories, hospitals, as well as players in the pharmaceutical and biotechnology industries, commercial molecular diagnostic laboratories, and consumer genomics companies. The company's product offerings are critical in facilitating comprehensive genomic studies, contributing significantly to advancements in genetic health and personalized medicine. Founded in 1998, Illumina has its headquarters in San Diego, California, and operates through two main segments: Core Illumina and GRAIL, the latter focusing on the development of Galleri, a groundbreaking multi-cancer early detection test. Illumina's commitment to innovation is evident in its continuous efforts to develop new solutions aimed at accelerating cancer diagnoses and enhancing blood-based detection methods for minimal residual disease, among other post-diagnostic applications.
Products and Services
Illumina's portfolio encompasses a comprehensive range of sequencing and array-based instruments, consumables, and services tailored for genomic analysis. These include:
- Sequencing and Array-based Instruments and Consumables: This category covers reagents, flow cells, and library preparation kits necessary for carrying out genomic sequencing and analysis. These tools enable researchers and clinicians to explore an organism's genetic material in comprehensive or targeted ways, depending on the needs of their studies or diagnostics.
- Whole-Genome Sequencing Kits: These kits are designed for sequencing the entire genomes of organisms ranging in size and complexity. Whole-genome sequencing is critical for understanding genetic predispositions to diseases, identifying mutations, and conducting other comprehensive genomic studies.
- Targeted Resequencing Kits: For studies focusing on exomes, specific genes, RNA, or other particular genomic regions, Illumina offers targeted resequencing kits. These kits are vital for focused genetic analysis, enabling precise study of regions of interest within the genome.
- Genomic Services: Beyond products, Illumina offers a range of services, including whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support. These services facilitate the application of Illumina's technologies across various research and medical scenarios, ensuring users can leverage the full potential of genomic analysis.
- Galleri: A pioneering multi-cancer early detection test developed by GRAIL, a segment of Illumina, that aims to revolutionize cancer diagnostics. Galleri is designed to detect signals of cancer in the body before symptoms appear, offering the potential for significantly improved outcomes through earlier detection.
All products and services offered by Illumina are marketed and distributed directly to customers, as well as through life-science distributors, ensuring a wide-reaching impact on the field of genomics.
